Journal
ALZHEIMERS & DEMENTIA
Volume 13, Issue 9, Pages 1004-1012Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2017.01.018
Keywords
Preclinical Alzheimer's disease; Secondary prevention; Cognitive composite; Amyloid PET; Longitudinal cognitive decline
Categories
Funding
- NIA/NIH [K01 AG051718, K24 AG035007]
- [P01 AG036694]
- [R01 AG046396]
Ask authors/readers for more resources
Introduction: Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials. Methods: We examined amyloid beta (A beta)-related change in several variations of the preclinical Alzheimer cognitive composite (PACC) and each individual PACC component in clinically normal (CN) older participants in the Harvard Aging Brain Study. We then examined the PACC variations in the Alzheimer's Disease Cooperative Study Prevention Instrument Study as a replication cohort. Results: A beta+ CN individuals demonstrated longitudinal decline on all individual PACC components and all PACC variations. Ab group differences emerged earlier when Free and Cued Selective Reminding Test Free Recall was included in the PACC. PACC decline was associated with Clinical Dementia Rating progression. Discussion: This independent data set and a replication cohort confirm the ability of the PACC to capture both early and late cognitive decline during the preclinical stages of Alzheimer's disease, which may prove advantageous in the prevention trial design. (C) 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available